Press Release. Adocia Reports Operational and Financial Results for the First Half of 2014

Size: px
Start display at page:

Download "Press Release. Adocia Reports Operational and Financial Results for the First Half of 2014"

Transcription

1 Press Release Adcia Reprts Operatinal and Financial Results fr the First Half f 2014 Majr clinical results reprted n tw frmulatins based n insulin Sund financial psitin with apprximately EUR 16 millin in cash at June 30,2014 Lyn (France), July 24, Adcia (Eurnext Paris : FR ADOC), a bitechnlgy cmpany specialized in the develpment f best-in-class medicines frm already apprved therapeutic prteins, annunces tday its financial results fr the six mnths ended June 30, IFRS half year financial results fr the perid frm January 1 st t June 30 th 2014 have been submitted t a limited review by financial auditrs and validated by ur Bard Meeting held n July 23, The 2014 half year financial reprt is available n Adcia s website, Financials/Dcumentatin/Financial Reprt. Significant events f the first half f 2014: Annuncement f remarkable clinical results, first with the prduct BiChaperne Cmb, cmbinatin f basal insulin glargine and fast insulin Lispr and, secndly, with ultra-fast acting insulin BiChaperne Lispr. Cntinuatin f clinical develpment fr bth frmulatins: April 2014 marked the initiatin f a Phase II dse-effect study with the frmulatin BiChaperne Lispr. In additin, the Cmpany expects during the secnd semester t cmmence a Phase II dse-effect study with the BiChaperne Cmb, a cmbinatin f lng-acting insulin glargine and fast-acting insulin lispr. In July the Cmpany cmmenced a third insulin based prduct: BiChaperne human insulin (HinsBet ) as an alternative t insulin analgs fr prandial glycemic cntrl. Strengthening the prtfli f insulin frmulatins: Adcia is develping a furth prduct: a cncentrated frmulatin f insulin Lispr (Lispr BiChaperne U300) t treat patients using insulin pumps and fr patients with severe insulin resistance, which requires substantial dses f insulin. Increase f the visibility f the cmpany in the USA, thrugh the implementatin f an ADR prgram (American Depsit Receipt) and the presentatin f the successful clinical results at the American Diabete Assciatin Scientific sessins. 1

2 We are particularly pleased with the perfrmance f ur tw innvative frmulatins f insulin. The interest shwn by several large pharmaceutical cmpanies fr these tw prducts cnfirms ur strategic chices. Our next gal is t license these tw prjects, while actively pursuing their develpment stated Gérard Sula, President and CEO f Adcia. Financial highlights as f June 30, 2014: The fllwing table summarizes the half-year financial statements reprted in accrdance with IRFS standards fr the six-mnth perid ended June 30, 2014 cmpared with the sixmnth perid ended June 30, 2013: In thusand - IFRS Rules 30/06/ /06/2013 Operating revenue Research and develpment expenses (6 607) (6 460) General and administrative expenses (826) (926) Operating expenses (7 433) (7 386) Operating incme (lss) (5 559) (4 647) Financial net incme Net incme (lss) (5 545) (4 622) Average number f shares (in thusands) Net lss per share (in ) (0,9) (0,7) A sund financial psitin: With the receipt in June f EUR 3.2 millin granted under the French research and develpment tax credit (Crédit d Impôt Recherche) the Cmpany reprted cash and cash equivalents at June 30, 2014 f EUR 15.9 millin. The Cmpany s burnt rate was EUR 3.5 millin fr the first six mnths f An peratinal lss f EUR 5.5 millin fr the first half f 2014 cmpared with EUR 4.6 millin fr 2013 semester: - Operatinal expenses are relatively flat at EUR 7.4 millin cmpared with the same perid last year: The increase in the clinical expenses fr the first half f the year have been ffset by decreases in preclinical and subcntracting expenses; - Operatinal incme f EUR 1.9 millin represents a decrease f 32% cmpared with the same perid in 2013, reflecting the decrease f the revenue. On June 30, 2013, the licensing revenues recrded in the Prfit and Lss accunt resulted frm the agreement signed in 2011 with Eli Lilly and terminated in July We cntinue t develp ur prtfli f prducts while maintaining ur strict plicy f managing expenses stated Valérie Danaguezian, Chief Financial Officer. Our cash burnrate is in line with ur frecast and ur cash psitin at apprximately EUR16 millin allws us t cnfidently ensure the financing f ur peratinal plan. 2

3 Upcming events: Belw is a list f events Adcia plans t participate in thrugh the end f the year: - SFAF (French Sciety f Financial Analyst): Presentatin f first half financial results September 9 - Large & Midcap Event: Octber, 2 and 3; Paris. - EASD (Eurpean Assciatin fr the Study f Diabetes): September 15-19; Vienna, - PODD (Partnership Opprtunities in Drug Delivery): Octber 14-15; Bstn - BIO Eurpe: Nvember 3-5; Frankfurt, - BBC (Bstn Bitech Cnferences): Nvember 12-13; New Yrk. Abut Adcia T be a glbal leader in the innvative delivery f insulins and therapeutic prteins. Adcia is clinical-stage bitechnlgy cmpany that specializes in the develpment f innvative frmulatins f already-apprved therapeutic prteins. It has a particularly strng expertise in the field f insulins. Adcia s prprietary BiChaperne technlgical platfrm is designed t enhance the effectiveness and safety f therapeutic prteins and their ease f use fr patients. Adcia has successfully cmpleted tw Phase I and IIa studies f a fast-acting human insulin frmulatin (HinsBet), tw Phase I and IIa studies f an ultra-fast-acting insulin lispr (BiChaperne Lispr U100), a Phase I/II f a unique cmbinatin f insulin glargine, the gld-standard f basal insulin and insulin lispr, a fast-acting insulin analg (BiChaperne Cmb) and ne Phase II clinical study f its prduct based n PDGF-BB fr treating diabetic ft ulcer (BC PDGF-BB). A dse-escalatin Phase IIa study f BiChaperne Lispr U100 is nging. The German regulatry agency apprved In July 2014 the start f a Phase IIa clinical study fr HinsBet and a dse-escalatin Phase IIa study f BiChaperne Cmb is scheduled fr the furth quarter Finally, the cmpany is preparing a first clinical study f a new ultra-fast cncentrated insulin frmulatin based n insulin lispr (BiChaperne Lispr U300) fr Adcia has extended its activities t the frmulatin f mnclnal antibdies, which are gld-standard bilgics fr the treatment f varius chrnic pathlgies (cancer, inflammatin, etc.). Adcia is engaged in cllabrative prgrams with tw majr pharmaceutical cmpanies in this field. Fighting cancer with targeted treatments DriveIn is a nantechnlgy which is remarkably efficient in delivering active cmpunds int cancer cells. This new platfrm cnstitutes an exceptinal pprtunity t enter the nclgy market by imprving the efficacy f bth already apprved treatments and nvel prprietary mlecules. Innvative medicine fr everyne, everywhere Adcia s therapeutic innvatins aim at prviding slutins in a prfundly changing glbal pharmaceutical and ecnmic cntext, characterized by (i) an increased prevalence and impact f the targeted pathlgies, (ii) a grwing and ageing ppulatin, (iii) a need t cntrl public health expenditures and (iv) an increasing demand frm emerging cuntries. Adcia is listed n the regulated market f Eurnext Paris (ISIN: FR ; Reuters/Blmberg ticker: ADOC, ADOC.PA, ADOC.FP) and its share price is included in the Next Bitech index. American Depsitary Receipts representing Adcia cmmn stck are traded n the US OTC market under the ticker symbl ADOCY. Fr mre infrmatin: 3

4 Cntact Gerard Sula - Chairman and CEO Tel.: Relatins média ALIZE RP Carline Carmagnl - Sphie Clin Tel.: Disclaimer This press release cntains certain frward-lking statements cncerning Adcia and its business. Such frward-lking statements are based n assumptins that Adcia cnsiders t be reasnable. Hwever, there can be n assurance that the estimates cntained in such frward-lking statements will be verified, which estimates are subject t numerus risks including the risks set frth in the Risk Factrs sectin f the Reference Dcument registered by the Autrite des marches financiers n April 24, 2014 under number R (a cpy f which is available n hhtp:// and t the develpment f ecnmic cnditins, financial markets and the markets in which Adcia perates. The frward-lking statements cntained in this press release are als subject t risks nt yet knwn t Adcia r nt currently cnsidered material by Adcia. The ccurrence f all r part f such risks culd cause actual results, financial cnditins, perfrmance r achievements f Adcia t be materially different frm such frward-lking statements. This press release and the infrmatin cntained herein d nt cnstitute an ffer t sell r the slicitatin f an ffer t buy Adcia shares in any jurisdictin. 4

5 APPENDIX: Financial Results as f June 30, 2014: Operating revenues The fllwing table shws details f peratinal prducts fr each perid: In thusands IFRS rules 30/06/ /06/2013 Research and cllabrative agreements 186 (47) Incme frm licenses Revenue (a) Grants, public financing and research tax credits (b) Operating revenues (a)+(b) Operating revenues fr the first half f 2014 ended June 30 decreased by 32% cmpared with thse reprted during the same perid in Revenue ttaling EUR 0.2 millin as f June 30, 2014 is essentially resulting frm nging research and cllabrative cntracts related t the frmulatin f mnclnal antibdies. Fr the same perid, last year, revenue was EUR 0.9 millin due t the amrtizatin f the initial up-frnt payment received under the cntract signed with Eli Lilly in December 2011 and terminated in July The ther perating revenues prducts are mainly cnstituted by the tax credit research fr a ttal amunt f apprximately EUR 1.8 millin cmpared with apprximately EUR 1.9 millin as f June 30, They are n line with the level f the research and develpment expenses eligible ver the perid cncerned. Operating expenses 30/06/ /06/2013 In thusands IFRS rules Research and develpment expenses (6 607) (6 460) General and administrative expenses (826) (926) Operating Expenses (7 433) (7 386) 5

6 Operating expenses at EUR 7.4 millin recrded in the first half were flat cmpared with thse reprted last year. Nearly 89% f peratinal expenses are related t research and develpment expenses, and reflected the cntinuatin f strng R&D activities and tight cntrl f general and administrative and ther verhead activity. External expenses, which represent nearly 52% f the ttal perating expenses were flat cmpared with last year s same perid: the decrease in preclinical and subcntracting expenses was ffset by the increase in the clinical expenses (+ EUR 1.2 millin) and reflected the develpment and the maturity f Adcia s pipeline. Wages and salaries represent the secnd significant area f expenses and represented 40% f ttal perating expenses, cmpared with 39% f ttal perating expenses fr the first half f Balance sheet incme In thusands IFRS rules 30/06/ /12/2013 Cash and cash equivalents Ttal Assets Equity Financial debts As f June 30, 2014, cash and cash equivalents ttaled EUR 15.9 millin, cmpared with EUR 19.4 millin as f December 31, Sharehlder s equity decreased frm EUR 19 millin at the end f December 2013 t EUR 13.9 millin at the end f June 2014, mainly reflecting the lss reprted fr the first six mnths f Outstanding debt, amunting t EUR 2.4 millin at the end f June 2014, mainly advances received frm the French Agency fr innvatin (Osé) abut steprsis and insulin prjects. 6

Press Release. Adocia: Activity and results for the first half of 2013

Press Release. Adocia: Activity and results for the first half of 2013 Press Release Adcia: Activity and results fr the first half f 2013 Intensificatin f R&D activity ahead f the launch f three clinical trials fr insulin prjects, starting in the secnd half f 2013 Net result

More information

Pancreatic Cancer Treatment Market Size, Share & Trends Analysis Report and Segment Forecast, 2025 Grand View Research, Inc

Pancreatic Cancer Treatment Market Size, Share & Trends Analysis Report and Segment Forecast, 2025 Grand View Research, Inc Pancreatic Cancer Treatment Market Size, Share & Trends Analysis Reprt and Segment Frecast, 2025 Grand View Research, Inc The rising prevalence f besity, alchl cnsumptin, and smking is expected t prpel

More information

Rate Lock Policy. Contents

Rate Lock Policy. Contents Rate Lck Plicy Cntents Rate Lcks... 2 Rate Lck Cnfirmatin... 2 Lck Term... 2 Pre-Lck... 2 Maximum Qualified Rate... 3 Extensins... 3 Cst t Extend... 3 Relcks... 4 Re-Negtiatin r Flat Dwn Plicy... 4 Prgram

More information

Electrosurgical Devices Market Size, Share & Trends Analysis Report and Segment Forecast, 2025 Grand View Research, Inc

Electrosurgical Devices Market Size, Share & Trends Analysis Report and Segment Forecast, 2025 Grand View Research, Inc Electrsurgical Devices Market Size, Share & Trends Analysis Reprt and Segment Frecast, 2025 Grand View Research, Inc Grwing awareness regarding mst recent surgical techniques in develping regins is expected

More information

The estimator, X, is unbiased and, if one assumes that the variance of X7 is constant from week to week, then the variance of X7 is given by

The estimator, X, is unbiased and, if one assumes that the variance of X7 is constant from week to week, then the variance of X7 is given by ESTIMATION PROCEDURES USED TO PRODUCE WEEKLY FLU STATISTICS FROM THE HEALTH INTERVIEW SURVEY James T. Massey, Gail S. Pe, Walt R. Simmns Natinal Center fr Health Statistics. INTRODUCTION In April 97, the

More information

Service Change Process. Gateway 1 High-level Proposition. Innovation project name: Patient Self-Monitoring/Management of Warfarin

Service Change Process. Gateway 1 High-level Proposition. Innovation project name: Patient Self-Monitoring/Management of Warfarin Service Change Prcess Gateway 1 High-level Prpsitin Innvatin prject name: Patient Self-Mnitring/Management f Warfarin NHS Bury Please describe the service change being prpsed. Please describe what service(s)

More information

Breast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)

Breast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018) Breast Cancer Awareness Mnth 2018 Key Messages (as f June 6, 2018) In this dcument there are tw sectins f messages in supprt f Cancer Care Ontari s Breast Cancer Awareness Mnth 2018: 1. Campaign key messages

More information

Activating the patient s immune system to fight. system to. Company presentation. fight cancer. Company presentation. August November

Activating the patient s immune system to fight. system to. Company presentation. fight cancer. Company presentation. August November Activating the patient s the immune system t fight immune cancer system t Cmpany presentatin fight cancer Cmpany presentatin August Nvember 2018 2018 Imprtant NOTICE AND DISCLAIMER This reprt cntains certain

More information

Risk factors in health and disease

Risk factors in health and disease Risk factrs in health and disease Index 1 Intrductin 2 Types f risk factrs 2.1 Behaviural risk factrs 2.2 Psychlgical risk factrs 2.3 Demgraphic risk factrs 2.4 Envirnmental risk factrs 2.5 Genetic risk

More information

A Unified Approach to Conflict Mineral Compliance for the Tungsten Industry. The Westin, Sydney, 23 September 2013

A Unified Approach to Conflict Mineral Compliance for the Tungsten Industry. The Westin, Sydney, 23 September 2013 A Unified Apprach t Cnflict Mineral Cmpliance fr the Tungsten Industry The Westin, Sydney, 23 September 2013 Backgrund Cmpliance f public US dwnstream tungsten users with the reprting requirements f the

More information

2016 CWA Political Action Fund Administrative Procedures Checklist

2016 CWA Political Action Fund Administrative Procedures Checklist 2016 CWA Plitical Actin Fund Administrative Prcedures Checklist 1. Dates f Prgram The 2016 CWA Plitical Actin Fund (federal plitical actin cmmittee- CWA-COPE PCC) Prgram will be cnducted n a calendar year

More information

Activating the patient s immune system to fight. system to. Company presentation. fight cancer. Company presentation. August November

Activating the patient s immune system to fight. system to. Company presentation. fight cancer. Company presentation. August November Activating the patient s the immune system t fight immune cancer system t Cmpany presentatin fight cancer Cmpany presentatin August Nvember 2018 2018 IMPORTANT NOTICE AND DISCLAIMER This reprt cntains

More information

Continuous Quality Improvement: Treatment Record Reviews. Third Thursday Provider Call (August 20, 2015) Wendy Bowlin, QM Administrator

Continuous Quality Improvement: Treatment Record Reviews. Third Thursday Provider Call (August 20, 2015) Wendy Bowlin, QM Administrator Cntinuus Quality Imprvement: Treatment Recrd Reviews Third Thursday Prvider Call (August 20, 2015) Wendy Bwlin, QM Administratr Gals f the Presentatin Review the findings f Treatment Recrd Review results

More information

Independent Charitable Patient Assistance Program (IPAP) Code of Ethics

Independent Charitable Patient Assistance Program (IPAP) Code of Ethics Independent Charitable Patient Assistance Prgram (IPAP) Cde f Ethics Independent charitable patient assistance prgrams (IPAPs) fcus n the needs f patients wh are insured, meet certain financial limitatin

More information

Intravascular Catheters Market Size, Share & Trends Analysis Report and Segment Forecast, 2025 Grand View Research, Inc

Intravascular Catheters Market Size, Share & Trends Analysis Report and Segment Forecast, 2025 Grand View Research, Inc Intravascular Catheters Market Size, Share & Trends Analysis Reprt and Segment Frecast, 2025 Grand View Research, Inc The glbal intravascular catheters market size was valued at USD 4.1 billin in 2018

More information

Amniotic Membrane Market Size, Share & Trends Analysis Report and Segment Forecast, 2025 Grand View Research, Inc

Amniotic Membrane Market Size, Share & Trends Analysis Report and Segment Forecast, 2025 Grand View Research, Inc Amnitic Membrane Market Size, Share & Trends Analysis Reprt and Segment Frecast, 2025 Grand View Research, Inc The glbal amnitic membrane market size was valued at USD 2.26 billin in 2017 and is estimated

More information

P02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017

P02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017 P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin Revisin 1.9 July 26, 2017 P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin TABLE OF CONTENTS TABLE OF CONTENTS...

More information

Oxford Immunotec Company Overview

Oxford Immunotec Company Overview Oxfrd Immuntec Cmpany Overview J.P. Mrgan Healthcare Cnference 2019 Oxfrd Immuntec Glbal PLC 94C Innvatin Drive Miltn Park, Abingdn Oxfrdshire, OX14 4RZ, United Kingdm Cmpany Number 08654254 www.xfrdimmuntec.cm

More information

Virus Filtration Market Size, Share & Trends Analysis Report and Segment Forecast, 2026 Grand View Research, Inc

Virus Filtration Market Size, Share & Trends Analysis Report and Segment Forecast, 2026 Grand View Research, Inc Virus Filtratin Market Size, Share & Trends Analysis Reprt and Segment Frecast, 2026 Grand View Research, Inc The glbal assisted walking device market is expected t reach ver USD 2.0 billin by 2024 accrding

More information

British Sign Language (BSL) Plan October 2018 Scottish Charity Regulator

British Sign Language (BSL) Plan October 2018 Scottish Charity Regulator British Sign Language (BSL) Plan 2018-2024 Octber 2018 Scttish Charity Regulatr Cntents Sectin 1: Intrductin and cntext 1.1 Intrductin 1.2 Our wrk and what we d Sectin 2: Our BSL Plan 2.1 Scttish Public

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AWARD NUMBER: W81XWH-14-1-0444 TITLE: Culd HER2 Hetergeneity Open New Therapeutic Optins in Patients with HER2- Primary Breast Cancer? PRINCIPAL INVESTIGATOR: Gary Ulaner, MD, PhD CONTRACTING ORGANIZATION:

More information

Swindon Joint Strategic Needs Assessment Bulletin

Swindon Joint Strategic Needs Assessment Bulletin Swindn Jint Strategic Needs Assessment Bulletin Swindn Diabetes 2017 Key Pints: This JSNA gives health facts abut peple with diabetes r peple wh might get diabetes in Swindn. This helps us t plan fr medical

More information

FDA Dietary Supplement cgmp

FDA Dietary Supplement cgmp FDA Dietary Supplement cgmp FEBRUARY 2009 OVERVIEW Summary The Fd and Drug Administratin (FDA) has issued a final rule regarding current gd manufacturing practices (cgmp) fr dietary supplements that establishes

More information

Novel methods and approaches for sensing, evaluating, modulating and regulating mood and emotional states.

Novel methods and approaches for sensing, evaluating, modulating and regulating mood and emotional states. Nvel methds and appraches fr sensing, evaluating, mdulating and regulating md and emtinal states. 2018 Jy Academic Grant Call fr Prpsals Intrductin The Annual Jy grant initiative aims t prmte and cntribute

More information

INTERIM REPORT JANUARY SEPTEMBER 2017

INTERIM REPORT JANUARY SEPTEMBER 2017 INTERIM REPORT JANUARY SEPTEMBER 2017 TELEPHONE CONFERENCE NO ONE SHOULD HAVE TO DIE WAITING FOR A NEW ORGAN Octber 27, 2017 MAGNUS NILSSON, CEO CHRISTOFFER ROSENBLAD, CFO NASDAQ OMX Stckhlm (mid cap):

More information

WCPT awards programme 2015

WCPT awards programme 2015 WCPT awards prgramme 2015 The WCPT awards prgramme recgnises utstanding cntributins and leadership by individual physical therapists and grups t the prfessin and/r glbal health at an internatinal level.

More information

Ontario 2018 provincial election issues backgrounder

Ontario 2018 provincial election issues backgrounder Ontari 2018 prvincial electin issues backgrunder Dietitians f Canada Pririties May 2018 Access t dietitians in Ontari s health system Diet is the #1 risk factr fr chrnic diseases that cst Ontari $90 billin

More information

REPORT ON OPERATIONS 2017 TELEPHONE CONFERENCE

REPORT ON OPERATIONS 2017 TELEPHONE CONFERENCE REPORT ON OPERATIONS 2017 TELEPHONE CONFERENCE NO ONE SHOULD HAVE TO DIE WAITING FOR A NEW ORGAN February 12, 2018 MAGNUS NILSSON, CEO CHRISTOFFER ROSENBLAD, CFO NASDAQ OMX Stckhlm (mid cap): XVIVO HIGHLIGHTS

More information

Commissioning Policy: South Warwickshire CCG (SWCCG)

Commissioning Policy: South Warwickshire CCG (SWCCG) Cmmissining Plicy: Suth Warwickshire CCG (SWCCG) Treatment Indicatin Criteria FreeStyle Libre Flash Cntinuus Glucse Mnitring System Type I Diabetes Prir apprval must be requested frm the Individual Funding

More information

ENT Devices Market Size, Share & Trends Analysis Report and Segment Forecast, 2022 Grand View Research, Inc

ENT Devices Market Size, Share & Trends Analysis Report and Segment Forecast, 2022 Grand View Research, Inc ENT Devices Market Size, Share & Trends Analysis Reprt and Segment Frecast, 2022 Grand View Research, Inc The glbal ENT devices market size was valued at USD 17.2 billin in 2016. It is estimated t prgress

More information

Trauma Devices Market Size, Share & Trends Analysis Report and Segment Forecast, 2025 Grand View Research, Inc

Trauma Devices Market Size, Share & Trends Analysis Report and Segment Forecast, 2025 Grand View Research, Inc Trauma Devices Market Size, Share & Trends Analysis Reprt and Segment Frecast, 2025 Grand View Research, Inc The glbal trauma devices market size was valued at arund USD 6.9 billin in 2017 and is anticipated

More information

Angiography Devices Market Size, Share & Trends Analysis Report and Segment Forecast, 2026 Grand View Research, Inc

Angiography Devices Market Size, Share & Trends Analysis Report and Segment Forecast, 2026 Grand View Research, Inc Angigraphy Devices Market Size, Share & Trends Analysis Reprt and Segment Frecast, 2026 Grand View Research, Inc The glbal angigraphy devices market size was valued at USD 9.8 billin in 2018 and is prjected

More information

Fee Schedule - Home Health Care- 2015

Fee Schedule - Home Health Care- 2015 Fee Schedule - Hme Health Care- 2015 01/01/2015 1600 E Century Ave Ste 1 PO Bx 5585 Bismarck ND 58506-5585 www.wrkfrcesafety.cm Cpyright Ntice The five character cdes included in the Nrth Dakta Fee Schedule

More information

Osteoporosis Fast Facts

Osteoporosis Fast Facts Osteprsis Fast Facts Fast Facts n Osteprsis Definitin Osteprsis, r prus bne, is a disease characterized by lw bne mass and structural deteriratin f bne tissue, leading t bne fragility and an increased

More information

PRESIDENT. June 18, President St. Rita School for the Deaf Search managed by Catholic Recruiter Associates

PRESIDENT. June 18, President St. Rita School for the Deaf Search managed by Catholic Recruiter Associates PRESIDENT June 18, 2018 1 CLIENT BACKGROUND St. Rita Schl fr the Deaf (http://www.srsdeaf.rg) is a Cathlic, c-educatinal, pre K-12 grade, in additin t a Career 2 prgram serving students up t age 22. Fr

More information

Intracranial Pressure (ICP) Monitoring Market Size, Share & Trends Analysis Report and Segment Forecast, 2025 Grand View Research, Inc

Intracranial Pressure (ICP) Monitoring Market Size, Share & Trends Analysis Report and Segment Forecast, 2025 Grand View Research, Inc Intracranial Pressure (ICP) Mnitring Market Size, Share & Trends Analysis Reprt and Segment Frecast, 2025 Grand View Research, Inc The glbal intracranial pressure mnitring devices market is expected t

More information

Immunisation and Disease Prevention Policy

Immunisation and Disease Prevention Policy Immunisatin and Disease Preventin Plicy Quality Area 2: Children s Health and Safety 2.1 Each child s health is prmted 2.1.4 Steps are taken t cntrl the spread f infectius diseases and t manage injuries

More information

Goldman Sachs Dynamo Strategy Index

Goldman Sachs Dynamo Strategy Index INDEX INFORMATION Ticker GSDYNMO5 RIC.GSDYNMO5 Thmsn Identifier Index Spnsr Gldman, Sachs & C. Currency USD Number f Underliers max. 8 Vlatility Target 5% Daily Vlatility Cntrl 5.50% Index Calculatr Slactive

More information

Lee County Florida Income Guideline Chart

Lee County Florida Income Guideline Chart NEIGHBORHOOD STABILIZATION PROGRAM OF LEE COUNTY BUYER-RELATED QUESTIONS 1. Why is NSP beneficial t yur buyers? Three key advantages make the NSP Prgram especially attractive t eligible buyers: 1) Investrs

More information

Improving Surveillance and Monitoring of Self-harm in Irish Prisons

Improving Surveillance and Monitoring of Self-harm in Irish Prisons HSE Mental Health Divisin Stewart s Hspital, Palmerstwn, Dublin 20 Tel: 01 6201670 Email: inf@nsp.ie www.nsp.ie Imprving Surveillance and Mnitring f Self-harm in Irish Prisns Prject Scpe Dcument 8 th June

More information

Organizational Capacity for Change and Patient Safety

Organizational Capacity for Change and Patient Safety Organizatinal Capacity fr Change and Patient Safety Debrah M. Nadzam, PhD, FAAN - Jint Cmmissin Resurces Lrrie Jnes-Hartley, MSN, CRRN-A - Durham Reginal Hspital Presentatin Objectives Briefly describe

More information

MGPR Training Courses Guide

MGPR Training Courses Guide MGPR Training Curses Guide fiscal cde 92107050921 1. Descriptin The training prgram supprted by MGPR is prpsed by a grup f excellent mentrs/educatrs, accmplished in Pesticides Management and Analysis,

More information

The data refer to persons aged between 15 and 54.

The data refer to persons aged between 15 and 54. Drug-related hspital stays in Australia 1993-2005 Prepared by Amanda Rxburgh and Luisa Degenhardt, Natinal Drug and Alchl Research Centre Funded by the Australian Gvernment Department f Health and Ageing

More information

Appendix C. Master of Public Health. Practicum Guidelines

Appendix C. Master of Public Health. Practicum Guidelines Appendix C Master f Public Health Practicum Guidelines 0 Gergia State University, Schl f Public Health Master f Public Health Practicum Guidelines Fr mre infrmatin, cntact Jessica Hwell Pratt, MPH Practicum

More information

Daily Balancing in Maestro

Daily Balancing in Maestro Daily Balancing in Maestr Successful Daily Balancing in Maestr is based n utilizing reprts that cntain key peratinal and financial infrmatin based n yur prperty s requirements Maestr has 3 Key Daily Reprts

More information

Medical Student Immunization Requirements

Medical Student Immunization Requirements Medical Student Immunizatin Requirements The State f Illinis cde, Reference: (110 ILCS 20) Cllege Student Immunizatin Act, requires students t prvide prf f immunity: Measles (Rubela), Mumps, Rubella (German

More information

Strategic Plan Publication No: EO-SP

Strategic Plan Publication No: EO-SP Strategic Plan 2017-2019 Publicatin N: EO-SP-170223 +61 2 9036 5002 www.pcg.rg.au pcg.ffice@sydney.edu.au This dcument was prepared by the PCG Executive Office PCG Publicatin number: EO-SP-170223 Psych-nclgy

More information

Benefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria

Benefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria Benefits fr Anesthesia Services fr the CSHCN Services Prgram t Change Effective fr dates f service n r after July 1, 2008, benefit criteria fr anesthesia will change fr the Children with Special Health

More information

The U.S. & The Global Fund to Fight AIDS, Tuberculosis and Malaria

The U.S. & The Global Fund to Fight AIDS, Tuberculosis and Malaria The U.S. & The Glbal Fund t Fight AIDS, Tuberculsis and Malaria The Glbal Fund t Fight AIDS, Tuberculsis and Malaria (Glbal Fund) is an independent, multilateral, financing entity designed t raise significant

More information

Photomedicine Devices And Technologies Market Size, Share & Trends Analysis Report and Segment Forecast, 2024 Grand View Research, Inc

Photomedicine Devices And Technologies Market Size, Share & Trends Analysis Report and Segment Forecast, 2024 Grand View Research, Inc Phtmedicine Devices And Technlgies Market Size, Share & Trends Analysis Reprt and Segment Frecast, 2024 Grand View Research, Inc The glbal phtmedicine devices and technlgies market accunted fr USD 314.9

More information

LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST

LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST OPTUM LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY / APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED

More information

This standard operating procedure applies to stop smoking services provided by North 51.

This standard operating procedure applies to stop smoking services provided by North 51. Authr Name/Title Melanie McIlvar, Bid Develpment Manager Authr Signature Date: 4 th September 2017 Apprver Name/Title Jasn Shelley, Grup Directr f QA/RA Apprver Signature Date: 4 th September 2017 Issue

More information

TELCOMMUNICATIONS CONSUMER PROTECTIONS CODE (C628:2012) EXPLANATORY STATEMENT

TELCOMMUNICATIONS CONSUMER PROTECTIONS CODE (C628:2012) EXPLANATORY STATEMENT TELCOMMUNICATIONS CONSUMER PROTECTIONS CODE (C628:2012) EXPLANATORY STATEMENT Intrductin This is the Explanatry Statement fr the revised Cmmunicatins Alliance Telecmmunicatins Cnsumer Prtectins (TCP) Industry

More information

Building Code 101 OWMC November 20, Ministry of Municipal Affairs and Housing

Building Code 101 OWMC November 20, Ministry of Municipal Affairs and Housing Building Cde 101 OWMC Nvember 20, 2015 Ministry f Municipal Affairs and Husing Disclaimer These slides are prvided by the Ministry f Municipal Affairs and Husing fr cnvenience nly The slides shuld nt be

More information

A fake medicine that passes itself off as a real, authorised medicine. (1)

A fake medicine that passes itself off as a real, authorised medicine. (1) Falsified medicines Index 1 Intrductin 2 Types f falsified medicines 3 Eurpean regulatin n falsified medicines 4 Risks f falsified medicines 5 Buying medicine nline safely 6 References 7 Further resurces

More information

Persistence Market Research

Persistence Market Research Ophthalmic Devices Market - Glbal Study n Ophthalmic Devices: Asia t Witness Highest Grwth by 2020 Persistence Market Research Glbal Ophthalmic Devices Market Will Reach $2,685.1 millin in 2020: Persistence

More information

Second Quarter 2009 Results. Analyst and Media Conference July 28, 2009 Zurich

Second Quarter 2009 Results. Analyst and Media Conference July 28, 2009 Zurich Secnd Quarter 2009 Results Analyst and Media Cnference July 28, 2009 Zurich This presentatin cntains frward lking statements which invlve risks and uncertainties. The actual perfrmance, results and timing

More information

Methadone Maintenance Treatment for Opioid Dependence

Methadone Maintenance Treatment for Opioid Dependence POLICY STATEMENT Methadne Maintenance Treatment fr Opiid Dependence APPROVED BY COUNCIL: May 2010 PUBLICATION DATE: Dialgue, Issue 2, 2010 Disclaimer: As f May 19, 2018 physicians n lnger require an exemptin

More information

SCALES NW HEARING PROTECTION PROGRAM

SCALES NW HEARING PROTECTION PROGRAM PURPOSE Expsure t excessive nise in the wrkplace can cause permanent hearing lss. The Hearing Prtectin Prgram has been established t help ensure that emplyees f Scales NW, Inc. d nt suffer health effects

More information

CDC Influenza Technical Key Points February 15, 2018

CDC Influenza Technical Key Points February 15, 2018 CDC Influenza Technical Key Pints In this dcument: Summary Key Pints U.S. Vaccine Effectiveness U.S. Flu Activity Update Summary Key Pints On Thursday, tw influenza-related reprts appeared in the Mrbidity

More information

Indirect Sales. Proof Policy. Indirect Channel. Version May Author: Credit Risk & Fraud. External version

Indirect Sales. Proof Policy. Indirect Channel. Version May Author: Credit Risk & Fraud. External version Prf Plicy Indirect Channel Versin 12 7 May 2015 Authr: Credit Risk & Fraud External versin 1 Table f Cntents Intrductin... 3 Distance Selling... 4 Face t Face Selling... 10 Additinal Prfs Plicy Infrmatin...

More information

Vaccine Impact Modelling Consortium

Vaccine Impact Modelling Consortium Vaccine Impact Mdelling Cnsrtium Annual meeting 2017 - Summary meeting reprt Windsr, UK February 28 March 2, 2017 Objectives f the Vaccine Impact Mdelling Cnsrtium The Vaccine Impact Mdelling Cnsrtium

More information

CDC Influenza Division Key Points November 7, 2014

CDC Influenza Division Key Points November 7, 2014 In this dcument: Summary Key Messages FluView Activity Update LAIV Effectiveness and Vaccinatin f Children H3N2 Match and Vaccinatin Vaccine Supply Summary Key Messages This week s FluView reprt indicates

More information

Digital Patient Monitoring Devices Market Size, Share & Trends Analysis Report and Segment Forecast, 2026 Grand View Research, Inc

Digital Patient Monitoring Devices Market Size, Share & Trends Analysis Report and Segment Forecast, 2026 Grand View Research, Inc Digital Patient Mnitring Devices Market Size, Share & Trends Analysis Reprt and Segment Frecast, 2026 Grand View Research, Inc The glbal digital patient mnitring devices market size was valued at USD 38

More information

Action plan: serialisation of Nordic packages focus on Product Codes

Action plan: serialisation of Nordic packages focus on Product Codes 19.6.2017, versin 5 Actin plan: serialisatin f Nrdic packages fcus n Prduct Cdes The aim f this dcument is t help pharma cmpanies t prepare fr prduct cde changes and t be able t maintain prduct cdes in

More information

EXECUTIVE SUMMARY INNOVATION IS THE KEY TO CHANGING THE PARADIGM FOR THE TREATMENT OF PAIN AND ADDICTION TO CREATE AN AMERICA FREE OF OPIOID ADDICTION

EXECUTIVE SUMMARY INNOVATION IS THE KEY TO CHANGING THE PARADIGM FOR THE TREATMENT OF PAIN AND ADDICTION TO CREATE AN AMERICA FREE OF OPIOID ADDICTION EXECUTIVE SUMMARY INNOVATION IS THE KEY TO CHANGING THE PARADIGM FOR THE TREATMENT OF PAIN AND ADDICTION TO CREATE AN AMERICA FREE OF OPIOID ADDICTION The Bitechnlgy Innvatin Organizatin (BIO) and ur member

More information

Related Policies None

Related Policies None Medical Plicy MP 3.01.501 Guidelines fr Cverage f Mental and Behaviral Health Services Last Review: 8/30/2017 Effective Date: 8/30/2017 Sectin: Mental Health End Date: 08/19/2018 Related Plicies Nne DISCLAIMER

More information

Statement of Work for Linked Data Consulting Services

Statement of Work for Linked Data Consulting Services A. Backgrund Infrmatin Statement f Wrk fr Linked Data Cnsulting Services The Natinal Library f Medicine (NLM), in Bethesda, Maryland, is a part f the Natinal Institutes f Health, US Department f Health

More information

SUMMARY THE EUROPEAN COMMUNITY STRATEGY

SUMMARY THE EUROPEAN COMMUNITY STRATEGY SUMMARY THE EUROPEAN COMMUNITY STRATEGY FOR THE PHASEOUT OF CFCS IN MDIS 1. The Eurpean Cmmunity s transitin strategy fr the phaseut f CFCs in metered-dse inhalers (MDIs) was submitted t the Parties t

More information

Transcatheter Embolization And Occlusion Devices Market Size, Share & Trends Analysis Report and Segment Forecast, 2026 Grand View Research, Inc

Transcatheter Embolization And Occlusion Devices Market Size, Share & Trends Analysis Report and Segment Forecast, 2026 Grand View Research, Inc Transcatheter Emblizatin And Occlusin Devices Market Size, Share & Trends Analysis Reprt and Segment Frecast, 2026 Grand View Research, Inc The glbal Transcatheter Emblizatin and Occlusin (TEO) devices

More information

Meeting Minutes. III. New Business (Slide Presentation is embedded for reference) [slides 3-47] May 2011 DMRAB Presentation PUBLIC C

Meeting Minutes. III. New Business (Slide Presentation is embedded for reference) [slides 3-47] May 2011 DMRAB Presentation PUBLIC C Cmmnwealth f Kentucky Cabinet fr Health and Family Services Department fr Medicaid Services Drug Management Review Advisry Bard Meeting May 12, 2011 Meeting Minutes Vting Members in attendance: Kim Crley,

More information

CLINICAL MEDICAL POLICY

CLINICAL MEDICAL POLICY Plicy Name: Plicy Number: Respnsible Department(s): CLINICAL MEDICAL POLICY Supervised Exercise Therapy fr Peripheral Artery Disease (PAD) MP-077-MD-DE Medical Management Prvider Ntice Date: 01/15/2019

More information

Cardiac Rehabilitation Services

Cardiac Rehabilitation Services Dcumentatin Guidance N. DG1011 Cardiac Rehabilitatin Services Revisin Letter A 1.0 Purpse The Centers fr Medicare and Medicaid Services (CMS) has detailed specific dcumentatin requirements fr Cardiac Rehabilitatin

More information

Endodontic Devices Market Size, Share & Trends Analysis Report and Segment Forecast, 2026 Grand View Research, Inc

Endodontic Devices Market Size, Share & Trends Analysis Report and Segment Forecast, 2026 Grand View Research, Inc Enddntic Devices Market Size, Share & Trends Analysis Reprt and Segment Frecast, 2026 Grand View Research, Inc The glbal enddntic devices market size was valued at USD 1.56 billin in 2018 and is expected

More information

D E R B Y, D E R B Y S H I R E, N O T T I N G H A M & N O T T I N G H A M S H I R E L M I S U M M A R Y

D E R B Y, D E R B Y S H I R E, N O T T I N G H A M & N O T T I N G H A M S H I R E L M I S U M M A R Y D E R B Y, D E R B Y S H I R E, N O T T I N G H A M & N O T T I N G H A M S H I R E L M I S U M M A R Y 2 A B O U T This dcument prvides a summary f key findings fr the Derby, Derbyshire, Nttingham and

More information

DATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 2016 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS

DATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 2016 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS DATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 216 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS This briefing has been specifically prepared fr the Ministry f Health t prvide infrmatin frm this

More information

August November 2018

August November 2018 Activating the patient s the immune system t fight immune cancer system t Cmpany presentatin fight cancer 3Q 2018 Reprt August 2018 1 Nvember 2018 Imprtant NOTICE AND DISCLAIMER This reprt cntains certain

More information

APESB and Auditor Independence

APESB and Auditor Independence APESB and Auditr Independence Financial Reprting Cuncil Audit Quality Cmmittee 14 May 2014 Channa Wijesinghe MBA, FCPA, FCA Technical Directr Overview Rle f the Accunting Prfessinal & Ethical Standards

More information

For personal use only

For personal use only Fr persnal use nly ASX / MEDIA RELEASE FOR IMMEDIATE RELEASE 10 May 2013 CROWN RECEIVES NSW GAMING REGULATORY APPROVALS MELBOURNE: Crwn Limited (ASX: CWN) annunced tday that it has received written advice

More information

2017 Annual Conference

2017 Annual Conference 2017 MCH Annual Cnference Spnsr and Exhibitr Guide 2017 Annual Cnference Hw Far Can We G? MCH Annual Cnference Cragun s Cnference Center Brainerd, MN September 26 & 27, 2017 2017 MCH Annual Cnference The

More information

Belgian Volition SA - a VolitionRx Company- Technological company presentation BIOWIN DAY 2014

Belgian Volition SA - a VolitionRx Company- Technological company presentation BIOWIN DAY 2014 Belgian Vlitin SA - a VlitinRx Cmpany- Technlgical cmpany presentatin BIOWIN DAY 2014 Abut VlitinRx Wh we are Lab and Head ffice in Namur, Belgium Creatin: Oct 2010 8 emplyees + Internatinal Bard f Directrs

More information

CONTACT: Amber Hamilton TYPE 2 DIABETES AND OBESITY: TWIN EPIDEMICS OVERVIEW

CONTACT: Amber Hamilton TYPE 2 DIABETES AND OBESITY: TWIN EPIDEMICS OVERVIEW FACT SHEET CONTACT: Amber Hamiltn 212-266-0062 TYPE 2 DIABETES AND OBESITY: TWIN EPIDEMICS OVERVIEW Type 2 diabetes accunts fr 90-95% f the 29.1 millin diabetes cases in the U.S. 1 Obesity is a majr independent

More information

A pre-conference should include the following: an introduction, a discussion based on the review of lesson materials, and a summary of next steps.

A pre-conference should include the following: an introduction, a discussion based on the review of lesson materials, and a summary of next steps. NAU Mdel Observatin Prtcl The mdel prtcl was develped with supprt and expertise frm the Natinal Institute fr Excellence in Teaching (NIET) and is based in great part n NIET s extensive experience cnducting

More information

Paediatric MRI Project Thames Valley and Wessex ODN

Paediatric MRI Project Thames Valley and Wessex ODN July 2 PAEDIATRIC MRI PROJECT THAMES VALLEY AND WESSEX ODN Paediatric MRI Prject Thames Valley and Wessex ODN IN THIS ISSUE February 2017 Welcme By Nadine Duffin Welcme t the third newsletter fr the Thames

More information

neuropharmaceuticals commericalization

neuropharmaceuticals commericalization neur neurpharmaceuticals cmmericalizatin neurnan pharma 11th Annual NanBusiness Cnference Nanmanufacturing Summit September 4-6, 2012 Bstn, MA neur I. Intrductin 2 Alexander Kabanv, C-funder UNC - Chapel

More information

CDC Influenza Division Key Points December 9, 2016

CDC Influenza Division Key Points December 9, 2016 In this dcument: Summary Key Pints Summary f Influenza Virus Labratry Data FluView Activity Update Early Influenza Vaccine Cverage Estimates fr 2016-17 Influenza Vaccine Prgram Impact Estimates fr 2015-16

More information

The Cannabis Act and Regulations

The Cannabis Act and Regulations The and Regulatins OVERVIEW The and Regulatins cme int frce n Octber 17, 2018 and replaces the Access t Cannabis fr Medical Purpses Regulatins (ACMPR), and any mentin f Cannabis and Marihuana in the Narctics

More information

Ancillary Symposia Request for Proposals Partner with the Endocrine Society to Educatte the Endocrine Community.

Ancillary Symposia Request for Proposals Partner with the Endocrine Society to Educatte the Endocrine Community. Ancillary Sympsia Request fr Prpsals Partnerr with the Endcrine Sciety t Educate the Endcrine Cmmunity. Jin the Endcrine Sciety in Bstn fr the 98 th Annual Meeting & Exp frm April 1 4, 2016. ENDO 2016

More information

Health Consumers Queensland submission

Health Consumers Queensland submission Health Cnsumers Queensland submissin Inquiry int Public Health (Medicinal Cannabis) Bill 2016 Queensland Parliament Health, Cmmunities, Disability Services and Family Vilence Preventin Cmmittee Cntact:

More information

AGRANA Beteiligungs-AG RCB Investors Conference in Zürs (April 9-10, 2008) Adding value to nature s gifts.

AGRANA Beteiligungs-AG RCB Investors Conference in Zürs (April 9-10, 2008) Adding value to nature s gifts. AGRANA Beteiligungs-AG RCB Investrs Cnference in Zürs (April 9-10, 2008) April 9, 2008 1 AGRANA at a glance AGRANA prducts yu meet everyday Sugar Sugar is sld - t cnsumers via the fd trade (20%) and -

More information

2017 CMS Web Interface

2017 CMS Web Interface CMS Web Interface CARE-2 (NQF 0101): Falls: Screening fr Future Fall Risk Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION...

More information

Retinal Surgery Devices Market Size, Share & Trends Analysis Report and Segment Forecast, 2025 Grand View Research, Inc

Retinal Surgery Devices Market Size, Share & Trends Analysis Report and Segment Forecast, 2025 Grand View Research, Inc Retinal Surgery Devices Market Size, Share & Trends Analysis Reprt and Segment Frecast, 2025 Grand View Research, Inc The glbal retinal surgery devices market size was estimated at USD 1.56 billin in 2016

More information

International Experts Meeting on Severe Accident Management in the Light of the Accident at the Fukushima Daiichi Nuclear Power Plant

International Experts Meeting on Severe Accident Management in the Light of the Accident at the Fukushima Daiichi Nuclear Power Plant IAEA-CN-233 Internatinal Experts Meeting n Severe Accident Management in the Light f the Accident at the Fukushima Daiichi Nuclear Pwer Plant Organized in cnnectin with the implementatin f the IAEA Actin

More information

Dental Benefits. Under the TeamstersCare Plan, you and your eligible dependents have three basic options when you need dental care.

Dental Benefits. Under the TeamstersCare Plan, you and your eligible dependents have three basic options when you need dental care. Dental Benefits Under the TeamstersCare Plan, yu and yur eligible dependents have three basic ptins when yu need dental care. Optin #1: TeamstersCare Dentists. Yu can use ur in-huse Charlestwn, Chelmsfrd,

More information

Food information to consumers - Commission proposal - COM (2008) 40 final 2008/0028 (COD) The European Heart Network s position in a nutshell

Food information to consumers - Commission proposal - COM (2008) 40 final 2008/0028 (COD) The European Heart Network s position in a nutshell Fd infrmatin t cnsumers - Cmmissin prpsal - COM (2008) 40 final 2008/0028 (COD) The Eurpean Heart Netwrk s psitin in a nutshell Summary On 30 January 2008 the Eurpean Cmmissin published its prpsal fr a

More information

Family Medicine Clinical Pharmacy Forum Vol. 3, Issue 5 (September/October 2007)

Family Medicine Clinical Pharmacy Forum Vol. 3, Issue 5 (September/October 2007) 1 Family Medicine Clinical Pharmacy Frum Vl. 3, Issue 5 (September/Octber 2007) Family Medicine Clinical Pharmacy Frum is a brief bi-mnthly publicatin frm the Family Medicine clinical pharmacists distributed

More information

VITAPRO. Detoxification properties of Apple pectin formulation, PROPECTIN. CENTRE D ETUDE ET DE VALORISATION DES ALGUES FINAL REPORT.

VITAPRO. Detoxification properties of Apple pectin formulation, PROPECTIN. CENTRE D ETUDE ET DE VALORISATION DES ALGUES FINAL REPORT. CENTRE D ETUDE & DE VALORISATION DES ALGUES 2400 Detxificatin prperties f Apple pectin frmulatin, PROPECTIN. VITAPRO FINAL REPORT PrPectin July 2015 CENTRE D ETUDE ET DE VALORISATION DES ALGUES PRESQU

More information

Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast,

Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, Transparency Market Research Dental Cnsumables Market - Glbal Industry Analysis, Size, Share, Grwth, Trends and Frecast, 2012 2018 Buy Nw Request Sample Published Date: July 2013 Single User License: US

More information

Activating the patient s immune system to fight. system to. Company presentation. fight cancer. 4Q and Full Year August 14 February

Activating the patient s immune system to fight. system to. Company presentation. fight cancer. 4Q and Full Year August 14 February Activating the patient s the immune system t fight immune cancer system t Cmpany presentatin 4Q and Full Year 2018 fight cancer August 14 February 2019 2018 IMPORTANT NOTICE AND DISCLAIMER This reprt cntains

More information

University College Hospital. Pump school Starting on an insulin pump. Children and Young People s Diabetes Service

University College Hospital. Pump school Starting on an insulin pump. Children and Young People s Diabetes Service University Cllege Hspital Pump schl Starting n an insulin pump Children and Yung Peple s Diabetes Service 2 If yu wuld like this dcument in anther language r frmat, r require the services f an interpreter,

More information